Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-11T07:49:20.877Z Has data issue: false hasContentIssue false
  • English
  • Français

X-ray powder diffraction data for rivaroxaban, C19H18ClN3O5S

Published online by Cambridge University Press:  16 December 2021

Hua Shao ,
Zhen Wang ,
Shu Xie  and
Bin Liu Open the ORCID record for Bin Liu [Opens in a new window]
Hua Shao
Affiliation:
Medical College, Yangzhou University, Yangzhou 225009, China Department of Vasculocardiology, Yangzhou Friendship Hospital, Yangzhou 225009, China
Zhen Wang
Affiliation:
Department of Vasculocardiology, Yangzhou Friendship Hospital, Yangzhou 225009, China
Shu Xie
Affiliation:
Department of Vasculocardiology, Yangzhou Friendship Hospital, Yangzhou 225009, China
Bin Liu*
Affiliation:
Department of Vasculocardiology, Yangzhou Friendship Hospital, Yangzhou 225009, China
*
a)Author to whom correspondence should be addressed. Electronic mail: lb710823@sina.cn
Get access Rights & Permissions [Opens in a new window]

Abstract

X-ray powder diffraction data, unit-cell parameters, and space group for rivaroxaban, C19H18ClN3O5S, are reported [a = 9.010(3) Å, b = 10.986(6) Å, c = 11.230(1) Å, α = 63.439(5)°, β = 74.355(4)°, γ = 78.133(3)°, unit-cell volume V = 952.87 Å3, Z = 2, ρcal = 1.519 g cm−3, and space group P1]. All measured lines were indexed and are consistent with the P1 space group. No detectable impurities were observed.

Keywords

rivaroxabanfactor Xa inhibitorX-ray powder diffraction
Type
Data Report
Information
Powder Diffraction , Volume 37 , Issue 1 , March 2022 , pp. 40 - 42
Check for updates
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press on behalf of International Centre for Diffraction Data

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ajmal, M., Friedman, J., Sipra, Q. U. A. R., and Lassar, T. (2021). “Rivaroxaban: expanded role in cardiovascular disease management – a literature review,” Cardiovasc. Ther. 2021, 8886210.CrossRefGoogle ScholarPubMed
Akao, M., Yasuda, S., Kaikita, K., Ako, J., Matoba, T., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., Matsui, K., and Ogawa, H. (2021). “Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis,” Am. Heart J. 236, 59–68.CrossRefGoogle ScholarPubMed
Langford, J. I. and Louër, D. (1991). “High-resolution powder diffraction studies of copper(II) oxide,” J. Appl. Crystallogr. 24, 149–155.CrossRefGoogle Scholar
Neumann, M. A. (2003). “X-cell: a novel indexing algorithm for routine tasks and difficult cases,” J. Appl. Crystallogr. 36, 356–365.CrossRefGoogle Scholar
Pawley, G. S. (1981). “Unit-cell refinement from powder diffraction scans,” J. Appl. Crystallogr. 14(6), 357–361.CrossRefGoogle Scholar
Shen, J., Tang, G. P., and Hu, X. R. (2017). CCDC 1810879: Experimental Crystal Structure Determination.Google Scholar